Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimization of ART in AIDS-Related Lymphoma
NCT07727642Recruiting
- Start
- May 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
Open-label trial of albuvirtide, cabotegravir and rilpivirine in human immunodeficiency virus infection (HIV) (3 arms). Primary endpoint: Virological Suppression Rate at 24 weeks. Started May 2026; status: recruiting.
02
Drugs
albuvirtidecabotegravirrilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07727642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07727642.